NuTide:701: a phase 1 trial to find the best dose and test the safety of a new drug called NUC-7738 in people with advanced solid tumours or lymphoma

A phase 1 trial testing an experimental treatment, NUC-7738 in people with lymphoma.

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT03829254

Trial aim and background 

The aim of this trial is to establish the safety, and work out the best dose, of a potential new treatment called NUC-7738 for people with lymphoma and other types of cancer.

This is a phase 1 (early phase) trial. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future.

Who can enter

Adults with high-grade and low-grade B cell non-Hodgkin lymphoma (NHL) Hodgkin's lymphoma (HL) and T-cell lymphomas which have come back after (relapsed), or not responded to (refractory) treatment may be eligible for this trial.

Locations

Recruitment is taking place in the following UK locations:

  • University of Edinburgh, Edinburgh
  • The Beatson West of Scotland Cancer Centre, Glasgow
  • The Christie NHS Foundation Trust, Manchester
  • Freeman Hospital, Newcastle
  • University of Oxford, Oxford

Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/ct2/show/NCT03829254 

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.